OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis $50.64 -0.84 (-1.63%) (As of 11/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesShort Interest About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$50.64▼$50.6450-Day Range$46.22▼$53.0052-Week Range$43.68▼$55.56Volume633 shsAverage Volume711 shsMarket CapitalizationN/AP/E Ratio16.36Dividend Yield0.63%Price TargetN/AConsensus RatingN/A Company OverviewHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More… Top investors are backing this “unlisted” stock (Ad)When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying attention. That’s why top firms like SoftBank and Maveron have already backed their latest venture, a company that’s transforming the $1.3 trillion vacation home market.Learn more about becoming a shareholder in this real estate disruptor before their share price chang Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Stock News HeadlinesHikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 95% Above Its Share PriceNovember 23, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC ADRNovember 18, 2024 | wsj.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 29, 2024 | Crypto 101 Media (Ad)This FTSE 100 stock looks good to me and I’d consider buying it nowSeptember 30, 2024 | uk.finance.yahoo.comPositive Report for Hikma Pharmaceuticals (HIK) from Berenberg BankSeptember 3, 2024 | markets.businessinsider.comHikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention DayAugust 20, 2024 | prnewswire.comKLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 monthsAugust 15, 2024 | prnewswire.comWe Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are ConservativeAugust 15, 2024 | finance.yahoo.comSee More Headlines HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed this year? Hikma Pharmaceuticals' stock was trading at $45.4110 at the beginning of 2024. Since then, HKMPY shares have increased by 11.5% and is now trading at $50.6425. View the best growth stocks for 2024 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Ex-Dividend for 9/30 Dividend8/19/2024Dividend Payable9/30/2024Today11/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HKMPY CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio16.63 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (OTCMKTS:HKMPY) was last updated on 11/29/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.